Skip to main content

Drug Interactions between anifrolumab and panobinostat

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

panobinostat anifrolumab

Applies to: panobinostat and anifrolumab

GENERALLY AVOID: The use of anifrolumab, a type 1 interferon (IFN) receptor antagonist antibody with other biologic therapies, including B-cell-targeted therapies may increase the risk of infections. Anifrolumab alone has been reported to increase the risk of infections, including serious and fatal infections. However, concomitant use of anifrolumab with these therapies has not been studied. In the randomized, double-blind, placebo-controlled, phase 3 study of anifrolumab in adult subjects with active Systemic Lupus Erythematosus (SLE) (n=365), if patients had received treatment with a biologic agent, or a B-cell-depleting agent (e.g., ocrelizumab, ofatumumab, obinutuzumab, rituximab), they were required to complete a wash-out period of at least 5 half-lives prior to enrolment in the study.

MANAGEMENT: Until further information is available, anifrolumab is not recommended for use in combination with biologics with immunosuppressant effects, including B-cell-targeted therapies such as ocrelizumab, ofatumumab, obinutuzumab, or rituximab.

References (1)
  1. (2022) "Product Information. Saphnelo (anifrolumab)." AstraZeneca Pty Ltd

Drug and food interactions

Moderate

panobinostat food

Applies to: panobinostat

GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of panobinostat. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Increased exposure to panobinostat may increase the risk of adverse effects such as nausea, vomiting, diarrhea, anorexia, peripheral edema, cardiotoxicity, ECG abnormalities, electrolyte disturbances, bleeding complications, hepatotoxicity, and myelosuppression.

Food may delay the rate of absorption of panobinostat, but does not significantly affect the overall extent of absorption. When a single oral dose of panobinostat was administered to 36 patients with advanced cancer 30 minutes after a high-fat meal, panobinostat peak plasma concentration (Cmax) and systemic exposure (AUC) were approximately 44% and 16% lower, respectively, compared to administration under fasting conditions. The median time to maximum concentration (Tmax) was prolonged by 2.5 hours.

MANAGEMENT: Patients should avoid consumption of grapefruit or grapefruit juice during treatment with panobinostat. The manufacturer also recommends avoiding star fruit, Seville oranges, pomegranate, and pomegranate juice. Panobinostat may be administered with or without food.

References (3)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. (2015) "Product Information. Farydak (panobinostat)." Novartis Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer